Healthcare cost and utilization for chimeric antigen receptor (CAR) T-cell therapy in the treatment of pediatric acute lymphoblastic leukemia: A commercial insurance claims database analysis.
Alex HooverPaige ReimcheDave WatsonLynn R TannerLaura GilchristMike FinchYoav H MessingerLucie M TurcottePublished in: Cancer reports (Hoboken, N.J.) (2024)
This real-world cost analysis shows for the first time the encompassing cost of CAR-T therapy for pediatric B-ALL patients in the US with commercial insurance. This study provides a valuable benchmark that can be used to analyze the financial implications of CAR-T therapy for pediatric B-ALL therapy on health systems.
Keyphrases
- cell therapy
- acute lymphoblastic leukemia
- healthcare
- health insurance
- end stage renal disease
- chronic kidney disease
- newly diagnosed
- affordable care act
- ejection fraction
- stem cells
- mesenchymal stem cells
- prognostic factors
- emergency department
- peritoneal dialysis
- acute myeloid leukemia
- replacement therapy
- long term care
- health information
- smoking cessation
- patient reported